RanizuRel (ranibizumab biosimilar)
/ Reliance Life Sci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 26, 2023
Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment.
(PubMed, BMJ Open Ophthalmol)
- "This systematic review of four RCTs demonstrated no significant difference in visual outcomes, retinal thickness outcomes, as well as meta-analysis of adverse events between biosimilar and reference ranibizumab therapies for nAMD treatment."
Journal • Retrospective data • Review • Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
1 to 1
Of
1
Go to page
1